FDA denies making a promise on opioids

Share this article:
Rep. Harold Rogers
Rep. Harold Rogers

Contrary to a claim by a Kentucky Republican congressman that he was assured by FDA that it would not approve new opioids unless they had abuse-deterrent formulations, the agency says it never made such a commitment. Rep. Harold Rogers made his claim in commenting to the New York Times on the agency's Oct. 25 approval of Zogenix's single-ingredient hydrocodone bitartrate analgesic Zohydro ER, the day after it said it had agreed to support regulatory restrictions on combination hydrocodone products.

The approval had “dismayed” public health advocates, the newspaper reported, noting that an advisory panel last December had voted 11-2 against it because it could lead to the same type of abuse and addiction as OxyContin before it was reformulated to deter abuse.

FDA Press Office spokesperson Morgan Liscinski said the agency's Office of Legislation “has reached out to Rep. Rogers' office regarding his comments.”

In an earlier statement on the controversy, FDA said it was “committed to ongoing efforts to reduce opioid misuse and abuse while seeking to ensure that patients in pain continue to have appropriate access to these products. We consider the development of opioid analgesics with abuse-deterrent properties to be a public health priority and are actively supporting product development in this area, but the science is still in its early stages and abuse-deterrent formulations are not available for most ER/LA analgesics. Accordingly, the FDA does not believe it is feasible at this time to require that all new solid oral dosage form opioids have abuse-deterrent properties.”

Share this article:

Email Newsletters

More in News

AstraZenca beefs up respiratory portfolio

AstraZenca beefs up respiratory portfolio

AstraZeneca has made an $875-million move to beef up its respiratory pipeline by making Almirall's lineup its own.

Amgen Q2 sales rise, company to lay off up to 2,900

Amgen Q2 sales rise, company to lay off ...

The majority of the layoffs will be in the US.

Doctors want to know how CMS plans to display Sunshine payment data

Doctors want to know how CMS plans to ...

Physician and industry trade groups are asking CMS to explain how context will be provided to the general public around the dollar sums drugmakers ascribe to doctors for things like ...